Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric risankizumab study in moderate to severe plaque psoriasis
jRCT2051210069Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, single-blind trial of risankizumab in plaque psoriasis (5 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of participants achieving PASI 75 and Percentage of participants achieving sPGA clear or almost clear. Started Nov 2021; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2051210069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210069.